- Home
- ANL vs HOWL Comparison
ANL vs HOWL Comparison
Compare ANL & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- HOWL
- Stock Information
- Founded
- ANL 2004
- HOWL 2017
- Country
- ANL Cayman Islands
- HOWL United States
- Employees
- ANL N/A
- HOWL N/A
- Industry
- ANL
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- HOWL Health Care
- Exchange
- ANL Nasdaq
- HOWL Nasdaq
- Market Cap
- ANL 61.8M
- HOWL 64.5M
- IPO Year
- ANL 2023
- HOWL 2021
- Fundamental
- Price
- ANL $1.79
- HOWL $1.42
- Analyst Decision
- ANL Hold
- HOWL Strong Buy
- Analyst Count
- ANL 1
- HOWL 5
- Target Price
- ANL N/A
- HOWL $7.20
- AVG Volume (30 Days)
- ANL 9.3K
- HOWL 147.5K
- Earning Date
- ANL 09-26-2025
- HOWL 11-06-2025
- Dividend Yield
- ANL N/A
- HOWL N/A
- EPS Growth
- ANL N/A
- HOWL N/A
- EPS
- ANL N/A
- HOWL N/A
- Revenue
- ANL N/A
- HOWL N/A
- Revenue This Year
- ANL N/A
- HOWL N/A
- Revenue Next Year
- ANL N/A
- HOWL N/A
- P/E Ratio
- ANL N/A
- HOWL N/A
- Revenue Growth
- ANL N/A
- HOWL N/A
- 52 Week Low
- ANL $1.10
- HOWL $0.60
- 52 Week High
- ANL $3.89
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- ANL 60.57
- HOWL 59.41
- Support Level
- ANL $1.65
- HOWL $1.29
- Resistance Level
- ANL $1.88
- HOWL $1.49
- Average True Range (ATR)
- ANL 0.10
- HOWL 0.07
- MACD
- ANL 0.00
- HOWL 0.01
- Stochastic Oscillator
- ANL 58.02
- HOWL 62.50
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.